Introduction {#s1}
============

Dopaminergic System in Compulsive Behaviors {#s1_1}
-------------------------------------------

Compulsion is the impossibility of self-stopping to execute a habitual action with known outcome, despite adverse consequences ([@B89]). Compulsive behaviors are hallmarks of obsessive-compulsive disorder (OCD) and drug addiction, among other psychiatric diseases. Checking behavior is very common in obsessive-compulsive spectrum disorders being characterized by the constant repetition of a certain routine, in a stereotyped or ritualistic way ([@B128]). A wide range of normal behaviors (e.g., checking, cleaning, hands washing, etc.) can turn into compulsive in OCD patients and in general, arises in response to obsessive and distressing thoughts inducing anxiety. Similarly, seeking and consuming drugs of abuse become compulsive in drug addicts As in OCD, anxiety plays a key role triggering compulsive drug consumption in experienced drug abusers. The same impairments in reward and punishment processing are observed in both conditions ([@B46]), which has led some authors to discuss OCD as a behavioral addiction ([@B60]).

One possible mechanism leading to compulsive behavior is framed within the incentive-sensitization theory of addiction which is that an amplified motivation ("wanting") for the drug develops during addiction without developing an amplified pleasurable ("liking") effect ([@B12]; [@B11]). Enduring sensitization of the reward/motivation circuit is involved in the induction of incentive-sensitization associated to drug seeking. The reward/motivation circuit is composed of midbrain dopamine neurons of the *substantia nigra* (SN) and ventral tegmental area (VTA), which target the dorsal and ventral tiers of the striatum, respectively. Dopamine neurons that project to the ventral striatum or nucleus accumbens (NAc) have been traditionally related to goal-oriented behaviors, whereas dopamine neurons that project to the dorsal striatum have been associated with habits acquisition ([@B43]; [@B130]; [@B132]; [@B123]).

Sensitization of the reward/motivation circuit is observed in rodents as the gradual increase in locomotor activity induced by repeated administration of a potentially addictive drug fixed dose ([@B86]; [@B92]). Locomotor sensitization is an endurable phenomenon as it is observable after weeks, months and even a year after drug withdrawal ([@B91]). It was early suggested that sensitization of the reward/motivation circuit contributes to the compulsive drug seeking ([@B91]). Accordingly, locomotor sensitization facilitates self-administration cocaine seeking reinstatement ([@B30]). Moreover, rats with extended access to cocaine self-administration show greater locomotor response to cocaine than rats with limited access ([@B45]). In addition, the neurochemical changes underlying locomotor sensitization to psychostimulants are also observed in compulsive drug seeking ([@B105]; [@B52]). These data support the early proposed correspondence between locomotor sensitization and compulsive drug seeking observed in humans ([@B91]; [@B122]). Mechanistically, repeated administration of drugs of abuse sensitizes mesolimbic dopamine circuits increasing dopaminergic neurotransmission. Psychostimulants, like cocaine or amphetamines, that block the plasma membrane dopamine transporter (DAT), induce a large increase of dopamine in the synaptic space in the striatum and NAc, thus activating locomotion ([@B105]). As in drug addiction, sensitization of the dopamine reward/motivation circuit contribute to compulsive behaviors seen in OCD. Indeed, the repeated activation of dopamine D2 receptors (D2Rs) is enough to induce locomotor sensitization and checking behavior in both rats and mice ([@B111]; [@B112]; [@B107]). Repeated administration of quinpirole, a D2R/D3R agonist, is an accepted model of OCD as it recapitulates face validity, through an increment of compulsive checking and stereotyped behavior, predictive validity, as seen by a decrease of compulsive behaviors after chronic treatment with serotonin reuptake inhibitors (SRI) and construct validity as brain structures involved in this model are shared with those in the pathology ([@B106]; [@B114]). In summary, repeated activation of dopamine transmission, either by pre-synaptic (dopamine release) or post-synaptic (activation of D2R) mechanisms lead to locomotor sensitization and compulsive behaviors.

The kappa opioid system is one of the most preponderant systems controlling dopamine transmission in the reward/motivation circuit. Evidence shows that kappa-opioid transmission opposes to the effects of dopamine; the acute activation of kappa opioid receptors (KORs) counteracts the locomotor activity induced by psychostimulants ([@B55]). Conversely, repeated KOR activation maintains and enhances compulsive and habitual drug seeking ([@B66]). Consumption of drugs of abuse induce a homeostatic enhanced kappa opioid transmission, probably contributing to the negative emotional states of dysphoria ([@B66]) triggering compulsive drug use ([@B21]). In fact, the blockade of KOR prevented stress- but not drug-induced reinstatement of nicotine ([@B62]), cocaine ([@B7]) and ethanol ([@B104]). In line with this finding, KOR blockade reverts dopaminergic changes in the dorsolateral striatum of amphetamine sensitized rats, without modifying their enhanced locomotor response to the drug ([@B5]). Thus, KOR system seems to enhance negative reinforcement increasing drug-value. In OCD, negative reinforcement is triggered by obsessions, which strengthen a given compulsion in order to avoid that obsession. Although it has not been directly tested, negative reinforcing could play a role on quinpirole sensitization. Indeed, D2R are involved in the generation of negative reinforcement. For example, place avoidance to a morphine- withdrawal-paired area was not developed in mice lacking the long isoform of D2R ([@B100]) and repeated quinpirole treatment during abstinence period reinstates cocaine and heroin seeking in an auto-administration paradigm, an effect related to sensitized locomotion to quinpirole ([@B30]), suggesting shared mechanisms between psychostimulant and quinpirole-induced sensitization. Moreover, the introduction of the home cage, but not a novel cage, to the open-field arena reduces locomotor sensitization and compulsive checking behavior ([@B113]), indicating that safety/familiar cues might compete with negative environmental cues that favor sensitization. Similarly to psychostimulant-induced sensitization, the repeated activation of KOR facilitates locomotor sensitization ([@B42]) and compulsive checking behavior ([@B85]) induced by repeated administration of quinpirole. Whether this potentiating effect is a consequence of enhanced negative reinforcement remains to be elucidated.

The thorough analysis carried out recently shows that the effect of the kappa-opioid system on dopaminergic transmission is complex: it depends on the dopamine pathway involved ([@B74]; [@B75]), and on the timing between the activation of the KOR receptor and the activation of the dopamine receptor ([@B20]). Consistent with this complexity, the potential therapeutic use of KOR ligands has been widely discussed. It has been proposed that KOR agonist may be clinically useful during the drug use phase, attenuating the drug induced hyperdopaminergia ([@B98]). On the other hand, a KOR antagonist may be useful in treating withdrawal syndrome induced by an increase in dynorphin expression after repeated drug consumption ([@B125]). Accordingly, it has been proposed that KOR partial agonist ([@B6]) could be a therapeutic option to treat both the compulsive drug intake and withdrawal symptoms in addicted individuals ([@B20]; [@B16]). In this review, we analyze the time/context-dependent modulation of dopaminergic correlates of behavioral sensitization and compulsivity.

Anatomical and Functional Crosstalk Between Kappa Opioid and Dopaminergic Systems in Striatal and Midbrain Regions {#s1_2}
------------------------------------------------------------------------------------------------------------------

### Striatal Regions {#s1_2_1}

KORs are Gi/o protein-coupled receptors highly expressed in the midbrain dopamine system ([@B70]). These receptors belong to the family of opioid receptors composed by mu (MOR), delta (DOR) and kappa (KORs). The endogenous agonists for these receptors are endorphins, enkephalin and dynorphin, respectively. In the striatum, dynorphin is synthetized by dopamine D1receptor (D1R)-containing medium-sized neurons (MSNs) that have recurrent axons activating KORs from the same nuclei ([@B69]). Electron microscopy images of rat NAc shows that KORs are found predominantly in DAT-containing presynaptic structures while a minor proportion of KORs localizes on dendrites in apposition to DAT ([@B108]; [@B63]). Immunofluorescent studies characterizing presynaptic-synaptosomal preparations from NAc show that KORs and D2Rs preferentially coexist in synaptosomes containing the dopamine synthetizing enzyme, tyrosine hydroxylase (TH) ([@B42]). Moreover, KORs are abundant in cell bodies of the NAc and striatum, and colocalize with D2Rs in a cell subpopulation ([@B42]). With genetic and molecular insights, it has been suggested that a 20% of total KOR binding in the striatum is observed in DA terminals ([@B121]). Moreover, [@B116] showed that both D1R and D2R MSNs express KOR with a higher preference for D1R containing MSNs ([@B116]). This anatomical data indicates that KORs are present pre and postsynaptically, regulating dopamine neurotransmission in the reward/motivation circuit.

Several experimental approaches show that the activation of KORs inhibits dopamine release. The acute activation of KORs by a systemic injection or the local infusion of agonists decreases the extracellular levels of dopamine in the NAc ([@B32]; [@B102]; [@B49]) and dorsal striatum ([@B51]). Supporting a tonic inhibitory action of KORs over dopamine neurotransmission, the direct infusion of the long-lasting and selective KOR antagonist nor-binaltorphimine (nor-BNI) ([@B13]) increases basal levels of dopamine in the NAc ([@B102]) and dopamine release in the dorsal striatum ([@B5]). Final evidence of KOR tonic inhibition of dopamine was shown in KOR knockout mice, which displayed increased extracellular levels of dopamine in the striatum and NAc ([@B22]). The mechanisms responsible for KOR inhibition of dopamine release are not completely elucidated. However, it is well known that the activation of KORs leads to the increase of K + and decrease of Ca2+ conductances, thus inducing cell hyperpolarization and blockade of vesicular neurotransmitter release ([@B15]; [@B71]).

Additionally*, in vitro* and *in vivo* functional data suggests that KORs modify dopamine extracellular levels by modulating the activity of DAT. For instance, the activation of KORs in EM4 cells that co-express KORs and DAT, lead to an increased uptake of dopamine measured by voltammetry ([@B63]). An *ex vivo* analysis also using voltammetry in disaggregated tissues, showed that a systemic injection of KOR agonist U-69593 increased dopamine uptake in the NAc ([@B117]). A similar recent article shows that nor-BNI blocks the increase of dopamine uptake in the ventral and dorsal striatum, induced by an acute systemic injection of MP1104, a mixed Kappa/Delta opioid receptor agonist ([@B4]). Nevertheless, the effect of KOR activation on dopamine uptake has yet not been not fully elucidated. The systemic administration of the KOR partial agonist nalmefene decreased striatal dopamine uptake dose dependently, quantified by fast scan cyclic voltammetry (FSCV) ([@B93]). Using a no-net flux microdialysis in adult male rats, blocking of KOR was accompanied by an increase in extraction fraction (Ed), which is an indirect measure of dopamine uptake ([@B23]; [@B5]), suggesting that tonic activation of KOR exerts an inhibitory control on DAT activity (dopamine uptake). These results highlight the complex role of endogenous KOR activity on dopamine uptake to control dopamine extracellular levels. Higher temporal resolution approaches such as FSCV have failed to show an effect of KOR on dopamine uptake ([@B34]; [@B37]; [@B59]), suggesting that KOR enhancing DAT activity in striatal regions needs an incubation period., KOR-mediated enhancement of DAT activity could be explained by an increase in the number of DAT on cell membranes induced by KOR activation, as reported in striatal synaptosomes and cell lines ([@B63]).

### Midbrain Regions {#s1_2_2}

Autoradiographic assays performed in the rat midbrain show significant binding for KORs on the rostrocaudal axis of the SN and VTA ([@B103]). On the other hand, electron microscopy data show that dynorphin-containing terminals synapse directly on TH positive dendrites in the SN and the VTA ([@B95]), suggesting that KORs localize in somatodendritic compartments of dopamine neurons. Striatal D1R-containing MSNs are one of the dynorphin inputs to midbrain dopamine neurons. Interestingly, blockage of KORs does not modify the inhibitory effect of D1R-MSNs to VTA dopamine neurons, indicating that this inhibition is mediated by GABA ([@B35]). KORs modulate somatodendritic responses of dopamine midbrain neurons. Electrophysiological studies show that the activation of KORs in the VTA hyperpolarizes and decreases the spontaneus firing rate of dopamine neurons ([@B72]). Consequently, the infusion of KOR agonists decreases somatodendritic dopamine efflux ([@B99]; [@B29]). However, this inhibitory effect of KORs on dopamine neurons seems to be circuit dependent. The infusion of kappa-opioid agonists in the VTA decreases dopamine release in the medial prefrontal cortex (mPFC) ([@B74]) but not in the NAc ([@B31]; [@B74]). Moreover, [@B74] found that KORs inhibit VTA dopamine neurons that project to the mPFC and basolateral amygdala, but not those that project to the NAc. In that same year, [@B47] showed that bath application of KOR agonists in mouse VTA slices induced a higher outward current in dopamine neurons that project to the NAc compared to those that project to the basolateral amygdala, indicating that KORs exert a greater inhibition of dopamine neurons that project to the NAc than to the amygdala. Furthermore, the activation of KOR decreases the amplitude of excitatory ([@B73]) and inhibitory ([@B48]) postsynaptic currents into midbrain dopamine neurons. Differences between species and the complex efferents proyections of VTA to mPFC and NAc ([@B120]; [@B17]) make it challenging to establish whether KORs inhibit selectively some of the neuronal dopamine populations in VTA. Nevertheless, the data summarized here indicates that KORs are in the soma and terminals of dopamine neurons, as well as in the inputs that regulate them, thus exquisitely positioned to control the synaptic activity of midbrain dopamine neurons.

Role of KORs Controlling Dopamine Neurotransmission in Psychostimulants-Induced Sensitization and Compulsive Behaviors {#s1_3}
----------------------------------------------------------------------------------------------------------------------

Drug addiction is a process that involves initially impulsive drug seeking associated with their positive-reinforcing effects. On the other hand, compulsivity is a personality trait observable in drug addicts. Several neuroadaptations in dopaminergic pathways have been proposed to account for compulsive drug seeking and intake following repeated exposure to drugs of abuse ([@B43]; [@B65]). One of the proposed hypotheses driving compulsive drug intake is the sensitization of its negative-reinforcing effects ([@B66]). The inhibitory control of kappa opioid system on dopamine release could contribute to the negative-reinforcing properties of drugs of abuse. However, the consequences of KOR activation on dopamine neurotransmission and compulsive drugs seeking seems to be complex and apparently contradictory. Indeed, dopamine release induced by amphetamine and cocaine is attenuated by concomitant administration of KOR agonists ([@B57]; [@B68]; [@B117]) and even decrease cocaine self-administration ([@B82]). Moreover, KORs exert an inhibitory feedback on dopamine release of the mesolimbic pathway in response to the sustained activation of post-synaptic D1R as occurs with repeated exposure to psychostimulants ([@B24]; [@B83]). Paradoxically, the activation of KORs can also facilitate dopamine release in the reward/motivation pathway ([@B49]; [@B50]) and psychostimulants consumption ([@B126]). [@B50] showed that after four days administering U69593, a KOR agonist, increased amphetamine induced dopamine release in the NAc. Recently, it was shown that blocking KORs reverses the changes in dopamine release and uptake in dorsal striatum that takes place during the locomotor sensitization induced by amphetamine ([@B5]). Altogether, these data suggest that the activation of KORs might also contribute to positive-reinforcing properties of drug of abuse ([@B20]).

In addition, KORs activation also seem to contribute to compulsive drug seeking; KORs blockade reduces cocaine ([@B126]), heroin ([@B94]) and methamphetamine ([@B127]) intake in rats with unlimited access to the drug ([@B126]). This effect is also evidenced in stress-induced drug seeking. For instance, the KOR knockout mice did not show cocaine place preference after forced swimming stress ([@B79]). The blocking of KORs attenuates the nicotine place preference induced by forced swim stress exposure ([@B101]). Interestingly, the blocking of KOR attenuates the cocaine and nicotine seeking induced by stress but did not affect seeking induced by a drug challenge ([@B7]; [@B62]). This facilitator KOR effect induced by stress seems to be mediated by the reward/motivation circuit ([@B98]; [@B125]). In an elegant study performed by Dr. Kauer and her group, it was shown that blocking KORs in the VTA, either previously or after an acute stress, inhibits the reinstaintment of cocaine-seeking, an effect associated to the rescue of long-term-potentiation of inhibitory synapses in dopamine neurons ([@B56]; [@B87]).

The facilitation of psychostimulants intake exerted by KORs seems to depend on a time-window regarding drug exposure. The administration of the KOR agonist U50488 1 h before cocaine exposure potentiates both cocaine place preference and the relative dopamine release evoked by cocaine in the NAc, while the opposite effects are observed when given 15 min before ([@B79]; [@B36]). Using intracranial self-stimulation [@B20] observed that the KOR agonist Salvinorin A, has an initial aversive and a delayed rewarding effect, accompanied by a decrease and an increase in stimulated dopamine release in the NAc, respectively. All together these data indicate a time-dependent effect of KOR activation on the rewarding properties of cocaine, and points to the stress-mediated KOR activation as a key player for the development of compulsive drug-seeking.

Quinpirole-Induced Locomotor Sensitization and Compulsive Behavior {#s1_4}
------------------------------------------------------------------

The facts that the dopamine system is involved in the generation of sensitization and compulsivity is strengthened by the behavior observed in rodents treated with the D2R agonist, quinpirole. Briefly, D2Rs are Gi coupled receptors widely expressed in the reward/motivation circuit; they are expressed somatodendritically and on axon terminals of dopamine neurons ([@B96]), and its activation decreases dopamine extracellular levels ([@B61]). In the striatum, D2Rs are also located postsynaptically on medium spiny neurons ([@B96]) and its activation inhibits the indirect pathway allowing locomotor activity.

Dr. Henry Szechtman began studying the effects of quinpirole on the behavior of rats ending the decade of 1980. Their initial findings showed that the acute administration of quinpirole has dose-dependent effect on locomotor activity. At low doses (0.03 mg/kg) it decreases locomotor activity, while at higher doses (\>0.5 mg/kg), it increments. ([@B38]). These effects are associated with the activation of high-affinity presynaptic D2Rs and low-affinity postsynaptic D2Rs, respectively ([@B119]). Unexpectedly, the repeated (every other day) administration of quinpirole induces a gradual and sustained increase in locomotion, resembling the locomotor sensitization induced by psychostimulants ([@B109]; [@B110]). The locomotor sensitizing effect was shown to depend on D2Rs, since mice deficient for this receptor do not develop locomotor sensitization to quinpirole ([@B41]).

At the beginning of the 90\'s, Szechtman and Eilam reported that along with locomotor sensitization, rats developed a stereotyped behavior, which is reinforced with each administration of quinpirole ([@B38]; [@B109]). Today, quinpirole repeated administration is a validated model for OCD ([@B112]; [@B113]; [@B39]; [@B106]; [@B114]), based on the observation that the behavior of rats becomes increasingly structured and inflexible, reminiscent of the ritual behavior characteristic of compulsive checking behavior ([@B111]; [@B114]). Recent studies show that repeated quinpirole also induces compulsive behaviors in mice, such as compulsive checking ([@B107]), behavioral inflexibility and compulsive chewing ([@B3]), the latter reverted by D2Rs blockade in the striatum, further supporting that repeated D2Rs activation is needed to induce compulsive behaviors. Together the data points to a crucial role of D2Rs within the midbrain dopamine pathways to induce locomotor sensitization and compulsivity. Repeated quinpirole administration primes cocaine-induced stereotyped behavior ([@B118]) and the locomotor effects of amphetamine ([@B26]), strengthening the idea that D2Rs activation underlie psychostimulant-induced sensitization and suggesting a shared mechanism between quinpirole and psychostimulants-induced sensitization. Interestingly, the sensitizing effect of repeated D2Rs activation seems to be stronger than that induced by psychostimulants, since every rat treated with quinpirole develop locomotor sensitization ([@B41]), while around sixty percent of rats sensitize to amphetamine ([@B40]; [@B18]).

Behavioral sensitization induced by repeated activation of D2Rs is accompanied by adaptations in the reward/motivation circuit. Rats sensitized with quinpirole have lower dopaminergic tone in the NAc, observed as decreased basal ([@B64]) and stimulated tonic and phasic dopamine release ([@B41]), indicating decreased dopamine release capacity of dopamine midbrain circuit. Synaptic dopamine levels in the NAc are controlled by the activity of both, DAT and dopamine neurons activity ([@B53]), which *in vivo* consists of tonic and burst firing ([@B129]; [@B54]). Previous reports show that quinpirole-sensitized rats display a smaller number of dopamine neurons in tonic and burst firing in the VTA ([@B97]). Together these data indicate that the decrease in dopamine release seen after quinpirole sensitization is a result of a decrease in the overall activity of dopamine neurons. The compulsive behavior and sensitized locomotor activity induced by the repeated treatment with quinpirole could be a consequence of sensitization of D2Rs, due to decreased dopaminergic tone in the NAc. Indeed, quinpirole-sensitized rats show an increase in the binding of dopamine D2R ([@B28]) and an increase in the affinity state of these receptors ([@B85]), supporting this hypothesis.

KOR-Dopamine Interactions in Quinpirole-Induced Compulsive Behaviors {#s1_5}
--------------------------------------------------------------------

Initial studies regarding the role of KOR in D2R-induced compulsive behaviors also came from Szechtman\'s lab. This group examined the concomitant administration of the KOR agonist U69593 with quinpirole on locomotor activity. Specifically, the authors administered subcutaneous injections to rats with a mixture U69593 and quinpirole, until 8 to 10 injections were completed. Contrary to the hypolocomotor effect of U69593 alone, hyperlocomotion was observed when administered concomitantly with low (presynaptic) and high (postsynaptic) doses of quinpirole. U69593 changed the hypolocomotor effect of a presynaptic dose of quinpirole to hyperlocomotion and enhanced the hyperlocomotor effect of a postsynaptic dose of quinpirole ([@B84]). Co-activation of KORs also accelerated the induction of locomotor sensitization and potentiated the effect of D2Rs activation, since the maximum locomotion achieved by the double treatment duplicates the locomotor effect induced by quinpirole alone ([@B84]; [@B42]). Co-activation of KORs also accelerates the acquisition of compulsive checking behavior ([@B85]). These potentiating effects of KORs on quinpirole-induced behaviors require KORs repeated activation. In fact, acute injection of the KOR agonist U69593 did not further modify the locomotor activity in rats sensitized with quinpirole ([@B42]). The mechanism of KOR potentiating D2R-induced sensitization is unknown. One possibility is that the endogenous kappa opioid system itself is mediating D2R-dependent sensitization. However, this possibility was discarded by showing that pre-administration of norBNI did not modify locomotor sensitization to quinpirole, suggesting that dynorphin is not released downstream D2R activation ([@B42]). This data does not rule out that dynorphin might have a role in sensitizing compulsive behaviors, for example, stress induces the release of dynorphin and activation of KORs which facilitates compulsive behaviors ([@B78]; [@B79]; [@B80]).

The crosstalk between D2Rs and KORs is complex and it seems to depend on whether the activation of both receptors is coincident or temporally separated. Anatomical data indicate that the crosstalk between D2Rs and KORs can occur presynaptically in axons and soma of dopamine neurons, as well as postsynaptically in MSNs of the striatum. Although it does not rule out a role for KORs located on axons of other neurochemical systems, the anatomical data strongly points to a direct role of KORs regulating D2Rs. Either acute or repeated, the activation of KORs decreases the inhibitory D2Rs function on dopamine neurons. Electrophysiology studies showed that the acute activation of KOR in dopamine neurons of the VTA and SN inhibits D2R-mediated inhibitory postsynaptic current, an effect mediated by pre and postsynaptic mechanisms as KOR decreases dopamine release and dynorphin blocks the inhibitory effect of bath applied dopamine ([@B48]). Neurochemical studies showed that the repeated activation of KORs blocks D2R-induced inhibition of dopamine release in the NAc ([@B49]). Moreover, coincident D2Rs and KORs acute activation decreases the inhibition of dopamine release in the NAc compared to the effect of each receptor alone ([@B42]). Thus, presynaptic KORs do not act additively or in synergy with presynaptic D2Rs, conversely, KORs either inhibit or occlude D2R inhibitory effect. This mechanism could explain the locomotor activating effect of an acute dose of KOR agonists concomitant to a low dose of quinpirole ([@B84]).

A recent study shows that KOR activation in the VTA mediates compulsive behavior measured as behavioral inhibition and marble burying ([@B1]), reinforcing the idea that KORs activation is indeed a trigger for compulsivity. Data published by [@B74]; [@B75] indicate that KORs and D2Rs interaction should take place on dopamine neurons targeting the mPFC ([@B74]; [@B75]). Notwithstanding, [@B47]; [@B48] found that KORs inhibition of D2R mediated IPSC takes place on dopamine neurons targeting the NAc ([@B47]; [@B48]). Together these data show that KOR interaction with D2R at the somatodendritic compartment of dopamine neurons could arise as a result of a crosstalk in the same dopamine neuron. Whether this happens in the mesolimbic or mesocortical projections is still controversial.

Remarkably, KOR was found in MSNs of the NAc ([@B42]; [@B116]), thus indicating that the potentiation of D2R-induced compulsive behavior can also arise by direct actions on the target cells of dopamine neurons. In this regard, it is worth mentioning that repeated administration of U69593 increases the amount of D2Rs in the high affinity state ([@B85]). Neurochemical data indicate that decreased dopamine extracellular levels is associated to D2Rs sensitization. KORs co-activation does not decrease further the extracellular levels of dopamine in the NAc already decreased by the repeated activation of D2Rs ([@B42]), ruling out a role for presynaptic KORs accelerating or potentiating the sensitization of D2Rs in the NAc through this mechanism. Therefore, KORs trigger slow molecular mechanisms that further sensitize the neurochemical and behavioral effects of D2Rs, suggesting that the locomotion sensitization enhancement could be due to an adaptive postsynaptic rather than a presynaptic effect. In this regard repeated activation of KORs can trigger the inhibition of D2R indirect striatal pathway switching D1R/D2R balance to D1R inducing compulsivity ([**Figure 1**](#f1){ref-type="fig"}).

![Integrative scheme of Kappa Opioid Receptors (KOR) control on direct (D1R) and indirect (D2R) striatal phatways. **(A)** KOR are located pre-sinaptically on dopamine terminals and post sinaptically in medium-sized neurons (MSNs). Its activation controls dopamine extracellular levels and its localization promotes the interaction with dopamine transporter (DAT) and dopamine D2 receptors. **(B)** The repeated exposure to a psychostimulant is accompanied by an increase in both dopamine extracellular levels and dynorphin. The activation of D1 and D2 receptors switch the balance to the D1R direct pathway promoting locomotor sensitization. **(C)** The co-administration of quinpirole and U69593 is accompanied by a decrease in dopamine extracellular levels. The concomitant activation of KOR and D2 receptors debilitates the D2 indirect pathway inducing compulsive behavior.](fphar-11-00057-g001){#f1}

Sex Differences of KOR-Dopamine Interactions in Compulsive Behaviors {#s1_6}
--------------------------------------------------------------------

Clinical studies have shown sex differences in compulsive behavior including compulsive drug seeking. An earlier onset of OCD symptoms is observed in men compared with women ([@B77]), with women showing more prevalence of contamination and cleaning symptoms ([@B67]). Regarding sex differences in drug addiction, clinical evidence indicates that while the use of drugs is more prevalent in men, women exhibit a faster progression than men into compulsive drug seeking ([@B58]; [@B44]).

Lately, pre-clinical evidence has strongly highlighted the neurobiological bases underpinning the sex differences in drug abuse observed in clinical studies ([@B8]). Early observations using no-net flux microdialysis showed that dopamine extracellular concentration in the dorsal striatum varies during the estrous cycle with higher levels in proestrus and estrus compared with diestrus. Moreover, while ovariectomy decreases striatal dopamine extracellular concentration in female rats, the castration of male rats does not modify dopamine striatal extracellular concentration ([@B131]), suggesting an important role of ovary hormones on dopamine activity. In addition, female hormones regulate the response to psychostimulants. Early *in vitro* experiments showed that estradiol plus progesterone restore amphetamine-induced dopamine release from striatal tissue obtained of ovariectomized female rats ([@B9]). More recently, fast scan cyclic voltammetry studies have shown that females exhibit greater electrically-stimulated dopamine release and uptake compared to males ([@B124]). These sex differences in dopamine neurotransmission can account for the higher cocaine and amphetamine seeking observed in females. ([@B90]; [@B27]).

The regulation of KOR on dopamine extracellular levels also shows sex differences ([@B19]). Using intracranial self-stimulation and cyclic voltammetry, [@B25] showed that the lower sensitivity to the acute anhedonic effect of a KOR agonist observed in female rats compared to male rats, is accompanied by an attenuated inhibition of stimulated dopamine release in the NAc ([@B25]). It has been suggested that estradiol contributes to the blunted inhibition of dopamine release observed in female rats after KOR activation ([@B2]). While the crosstalk between KORs and dopamine signaling has been studied in males ([@B115]), research on this interaction and its impact in the addiction process in females is lacking ([@B19]). In female rats, the acute administration of the KOR agonist U69593 attenuated cocaine-induced hyperlocomotion in both, control and ovariectomized rats. Interestingly, U69593 repeated administration attenuated cocaine-induced hyperlocomotion in an estradiol-dependent manner ([@B88]). These data suggest that estradiol primes KOR actions in female rats, an effect that could be related to sex differences in stress response ([@B88]). Whether in female rats the repeated activation of KORs facilitates striatal dopamine release as observed in male is an unanswered question.

Although a facilitation in psychostimulant induced dopamine release is observed in female compared to male rats, sex differences in the dopamine mechanisms underlying amphetamine locomotor sensitization have not been fully elucidated ([@B10]). The repeated exposure to amphetamine induces a greater locomotor activity in both, adolescent ([@B76]) and adult female rats ([@B81]), with female adolescent rats showing a more robust locomotor sensitization after repeated exposure to amphetamine. The neonatal activation of D2 receptor potentiated the amphetamine induced behavioral sensitization only in female rats ([@B14]). As mentioned before, it has been observed in male rats the repeated exposure to D2 agonist induces locomotor sensitization and compulsive-like behavior ([@B33]). Moreover, the co-activation of KOR potentiates the locomotor sensitization induced by repeated exposure to quinpirole, facilitating the inhibitory control of D2 receptors on DA release in the NAc ([@B42]). Sex differences such as the observed lower sensitivity to the inhibitory effect of KOR on dopamine release in females ([@B25]) may account for a differential contribution of KOR on compulsive drug seeking.

Conclusions {#s2}
===========

How do KORs modulate dopamine signaling to elaborate motivated behaviors and when does it result in a sensitized compulsive behavior? Anatomical data shows that KORs are exquisitely positioned to control the synaptic activity of midbrain dopamine neurons. Functional data indicate that KORs control DAT and D2R functioning as well as dopamine neurons firing rate. Initial evidence showing that the acute activation of KORs decreases dopamine release induced by drugs of abuse has been complemented with data indicating that the repeated activation of KOR facilitates dopamine release and compulsive drug-seeking. Dopamine signaling balance direct and indirect output pathways from striatal areas ([**Figure 1A**](#f1){ref-type="fig"}). Either chronic stimulation with psychostimulants that increases dopamine release activating both D1R and D2R ([**Figure 1B**](#f1){ref-type="fig"}) or quinpirole that activate only D2R ([**Figure 1C**](#f1){ref-type="fig"}) results in locomotor sensitization and compulsive behaviors by a debilitated D2R indirect pathway, thus switching the balance to the D1R direct pathway. KOR transmission is enhanced during chronic psychostimulant intake by the increase of dynorphin in striatal D1 neurons ([**Figure 1B**](#f1){ref-type="fig"}). An enhanced KOR transmission is emulated in the pharmacological model of OCD by administering U69593. This concomitant KOR activation further debilitates the D2 indirect pathway ([**Figure 1C**](#f1){ref-type="fig"}). Future research should be carried out to fully elucidate the consequences of KOR activation on the DAT activity, understand the role of endogeous KOR system in the quinpirole induced compulsivity and determine the contribution of KOR system to the sex diffences observed in compulsive behaviors.
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